CR20150457A - Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos - Google Patents

Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos

Info

Publication number
CR20150457A
CR20150457A CR20150457A CR20150457A CR20150457A CR 20150457 A CR20150457 A CR 20150457A CR 20150457 A CR20150457 A CR 20150457A CR 20150457 A CR20150457 A CR 20150457A CR 20150457 A CR20150457 A CR 20150457A
Authority
CR
Costa Rica
Prior art keywords
compositions
modulators
modifying enzymes
methods modifying
methods
Prior art date
Application number
CR20150457A
Other languages
English (en)
Inventor
Brian K Albrecht
James Edmund Audia
Andrew S Cook
Les A Dakin
Martin Duplessis
Victor S Gehling
Jean-Christophe Harmange
Christopher G Nasveschuk
Rishi G Vaswani
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239937&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150457(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/025639 external-priority patent/WO2013120104A2/en
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CR20150457A publication Critical patent/CR20150457A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Agentes para modular las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos.
CR20150457A 2013-02-11 2015-09-02 Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos CR20150457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/025639 WO2013120104A2 (en) 2012-02-10 2013-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof
PCT/US2014/015706 WO2014124418A1 (en) 2013-02-11 2014-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
CR20150457A true CR20150457A (es) 2015-10-20

Family

ID=50239937

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150457A CR20150457A (es) 2013-02-11 2015-09-02 Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos

Country Status (17)

Country Link
EP (1) EP2953941B1 (es)
KR (1) KR102219441B1 (es)
CN (1) CN105102446B (es)
CL (1) CL2015002239A1 (es)
CR (1) CR20150457A (es)
HK (1) HK1218648A1 (es)
IL (1) IL239985B (es)
MA (1) MA38341B1 (es)
ME (1) ME02730B (es)
PE (1) PE20160044A1 (es)
PH (1) PH12015501720A1 (es)
PL (1) PL2953941T3 (es)
RS (1) RS56207B1 (es)
SG (1) SG11201506077XA (es)
SI (1) SI2953941T1 (es)
TW (1) TWI629273B (es)
WO (1) WO2014124418A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MY186837A (en) 2014-12-23 2021-08-25 Novartis Ag Triazolopyrimidine compounds and uses thereof
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2017018975A1 (en) 2015-07-24 2017-02-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
JP2018522045A (ja) * 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) * 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
KR20180058829A (ko) 2015-10-06 2018-06-01 에피자임, 인코포레이티드 Ezh2 억제제로 수모세포종을 치료하는 방법
EP3674709A1 (en) 2015-11-05 2020-07-01 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム，インコーポレイティド 癌を処置するための併用療法
CN105669647B (zh) * 2016-02-22 2018-05-04 上海皓元生物医药科技有限公司 一种组蛋白甲基化酶ezh2抑制剂中间体的合成方法
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
RU2754856C2 (ru) 2016-06-20 2021-09-08 Новартис Аг Кристаллические формы соединения триазолопиримидина
CN109906224B (zh) 2016-06-20 2022-02-25 诺华股份有限公司 ***吡啶化合物及其应用
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
CA3039059A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
AU2017367768A1 (en) 2016-12-02 2019-07-18 Epizyme, Inc. Combination therapy for treating cancer
CN110191722B (zh) 2017-01-19 2022-03-01 第一三共株式会社 用于治疗htlv-1相关性脊髓病的药物组合物
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018231973A1 (en) 2017-06-13 2018-12-20 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US20210161883A1 (en) 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
WO2019094552A1 (en) * 2017-11-09 2019-05-16 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP7201400B2 (ja) 2017-11-14 2023-01-10 ファイザー・インク Ｅｚｈ２阻害剤組合せ療法
CN109879790B (zh) * 2017-12-06 2022-09-20 华东师范大学 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法
CN111757734A (zh) 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
ES2923290T3 (es) 2018-01-31 2022-09-26 Mirati Therapeutics Inc Inhibidores de PRC2
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
JP7453916B2 (ja) 2018-03-14 2024-03-21 バイオジェン・エムエイ・インコーポレイテッド Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グリコピラノシダーゼ阻害剤
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA3104209A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
SG11202102379XA (en) 2018-09-19 2021-04-29 Biogen Ma Inc O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US20220017506A1 (en) 2018-12-05 2022-01-20 Biogen Ma Inc. Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2020139339A1 (en) 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
US20220106305A1 (en) 2019-02-04 2022-04-07 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
JP2022524077A (ja) 2019-03-08 2022-04-27 バイオジェン・エムエイ・インコーポレイテッド アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
EP4003343A1 (en) 2019-07-24 2022-06-01 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021086966A1 (en) 2019-10-29 2021-05-06 Biogen Ma Inc. Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US20230286972A1 (en) 2020-08-03 2023-09-14 Biogen Ma Inc. Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536179B2 (en) * 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
ES2951688T3 (es) * 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9085583B2 (en) * 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
IL239985A0 (en) 2015-09-24
MA38341B1 (fr) 2018-11-30
MA38341A1 (fr) 2018-01-31
SI2953941T1 (sl) 2017-08-31
TWI629273B (zh) 2018-07-11
ME02730B (me) 2017-10-20
CL2015002239A1 (es) 2016-02-05
EP2953941A1 (en) 2015-12-16
SG11201506077XA (en) 2015-08-28
PE20160044A1 (es) 2016-02-11
EP2953941B1 (en) 2017-04-05
RS56207B1 (sr) 2017-11-30
KR102219441B1 (ko) 2021-02-23
CN105102446B (zh) 2018-01-23
PH12015501720B1 (en) 2015-11-09
PL2953941T3 (pl) 2017-11-30
WO2014124418A1 (en) 2014-08-14
HK1218648A1 (zh) 2017-03-03
CN105102446A (zh) 2015-11-25
PH12015501720A1 (en) 2015-11-09
KR20150119201A (ko) 2015-10-23
TW201443038A (zh) 2014-11-16
IL239985B (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CR20150457A (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CR20150462A (es) Inhibidores de erk y sus usos
CL2018003366A1 (es) Anticuerpos anti -cd40 y sus usos
CR20150549A (es) Compuestos heterocíclicos y sus usos
EA201591474A1 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
PE20151997A1 (es) Compuestos heterociclicos y usos de los mismos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201400080A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
SV2017005395A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
CL2016001367A1 (es) Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).